Background Infection with human papillomavirus (HPV) and diseases caused by HPV are
common in boys and men. We report on the safety of a quadrivalent vaccine (active against …

Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …

CERVICAL CANCER IS A MAJOR health problem, particularly in developing countries
where over 80% of global incidence and deaths from the disease occur, with estimated age …

Human papillomavirus (HPV) is the most common newly diagnosed sexually transmitted
infection in the United States. Although the majority of sexually active adults will be infected …

Published data to date indicate that human papillomavirus (HPV) prevention vaccines are
safe and efficacious in reducing HPV persistence and cervical intraepithelial neoplasia …

Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18
have been shown to be highly efficacious for preventing precursor lesions although the …

Abstract Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV)
L1 virus-like-particle (VLP) vaccine has been shown to be 95%–100% effective in …

The discovery of the association between infection by the human papillomavirus (HPV) and
the development of cervical cancer has been the foundation for establishing HPV as the …

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …

Vaccination against human papillomavirus (HPV) promises to dramatically decrease the
incidence of HPV-related diseases, including cervical cancer. Although this vaccine is …